1,721,086 research outputs found
The cytopathologist's expanding role in the 2018 updated molecular testing guidelines for lung cancer
No full textThe College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) International joint committee has recently updated the previous 2013 molecular guidelines version. Here we summarize these changes which demonstrate that molecular cytopathology is here to stay
Warthin tumor with signet-ring cell features as a pitfall in salivary gland cytopathology.
No full textHistological and fine needle aspiration cytological features of Hashimoto thyroditis-associated ?angiomatoid? papillary thyroid carcinoma
No full textHow should a follicular adenoma with papillary architecture be classified on thyroid FNA? Case report with histological correlation
No full textBiopsic Sampling (cancer) comprehensive sampling and sample preparation
No full textVirtually all forms of organ injury involve structural alterations in cells and tissues. The practice of pathology is devoted to
investigating and diagnosing diseases by studying these morphologic changes.1 This can be achieved by two different but
complementary approaches. Histopathology involves both the macroscopic and light microscopic examination of tissues, whose
architecture is retained; cytopathology specimens are composed of cells that are dissociated from their surrounding tissues without
preserving the histologic architecture. Histopathology is usually the primary mode for tumor diagnosis, which is supplemented with
prognostic information by tumor grading and staging.1 This section examines the sampling issues related to istopathology, and the following section focuses on cytopathology
Diffuse large B-cell extranodal lymphoma of the uterine cervix: An incidental pap smear finding with histological and immunohistochemical correlation.
No full textIntra-institutional second opinion diagnosis can reduce unnecessary surgery for indeterminate thyroid FNA: A preliminary report on 34 cases
No full textIndeterminate diagnoses are rendered on 15%-30% of thyroid fine-needle aspirates (FNA). Thus, a second diagnostic opinion given by an outside expert pathologist is a common practice that facilitates a more appropriate clinical management. Conversely, the role of an intra-institutional second opinion diagnosis (iSOD), which is usually informally performed in-house, has not been well established
Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?
No full textObjective: Guidelines from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP) consider cytology suitable for testing epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma. The guidelines recommend that cytopathologists first discuss the possibility of testing squamous cell carcinomas (SqCC) in multidisciplinary meetings. Second, cell blocks should be analysed rather than smear preparations and, third, specimens should be sent to external molecular laboratories within three working days of receiving requests. This study monitored how these recommendations are met in practice.
Methods: Our laboratory received 596 requests from cytologists from 13 different institutions. For each case, the cytological diagnosis, cytopreparation type, and time between the request and sample mailing were compared with the recommendations.
Results: Of the 596 samples, 32 (5.4%) had been reported as SqCC. Three of these (9.4%) showed EGFR mutation. Cytological slides, either ThinPrep TM (51.2%) or direct smears (43.2%), weremore frequently received than cell blocks (5.7%). The mean time between the oncologist's request and specimen dispatching was 5.8 working days.
Conclusions: The occurrence of mutations in samples reported as SqCC was higher than expected. This questions the reliability of the original diagnosis, which reinforced the recommendation to evaluate the opportunity for testing non-adenocarcinoma cytology on a case-by-case basis. In spite of CAP/IASLC/AMP recommendations, cell blocks were underutilized for EGFR testing, but cytological slides were suitable for DNA analyses. Significant efforts are needed to avoid delays in outsourcing cytological samples for EGFR testing
- …
